Original Article
A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine against Plasmodium falciparum Malaria
N Engl J Med 1997; 336:86-91January 9, 1997
- Abstract
Background
The candidate vaccines against malaria are poorly immunogenic and thus have been ineffective in preventing infection. We developed a vaccine based on the circumsporozoite protein of Plasmodium falciparum that incorporates adjuvants selected to enhance the immune response.
Methods
The antigen consists of a hybrid in which the circumsporozoite protein fused to hepatitis B surface antigen (HBsAg) is expressed together with unfused HBsAg. We evaluated three formulations of this antigen in an unblinded trial in 46 subjects who had never been exposed to malaria.
Results
Two of the vaccine formulations were highly immunogenic. Four subjects had adverse systemic reactions that may have resulted from the intensity of the immune response after the second dose, which led us to reduce the third dose. Twenty-two vaccinated subjects and six unimmunized controls underwent a challenge consisting of bites from mosquitoes infected with P. falciparum. Malaria developed in all six control subjects, seven of eight subjects who received vaccine 1, and five of seven subjects who received vaccine 2. In contrast, only one of seven subjects who received vaccine 3 became infected (relative risk of infection, 0.14; 95 percent confidence interval, 0.02 to 0.88; P<0.005).
Conclusions
A recombinant vaccine based on fusion of the circumsporozoite protein and HBsAg plus a potent adjuvant can protect against experimental challenge with P. falciparum sporozoites. After additional studies of protective immunity and the vaccination schedule, field trials are indicated for this new vaccine against P. falciparum malaria.
Media in This Article
Figure 1
Geometric Mean Responses of Antibody against Circumsporozoite Tandem-Repeat Epitopes after the Administration of the Vaccines.Table 1
Titers of Antibodies against Circumsporozoite Tandem-Repeat Epitopes and Intact Sporozoites at the Time of Sporozoite Challenge.Article Activity
- Article
Plasmodium falciparum malaria causes more than 2 million deaths annually,1 and there is currently no effective vaccine to prevent it. The bite of an infected anopheles mosquito introduces sporozoites into the microvasculature, which are carried to the liver. After invading hepatocytes, sporozoites develop into merozoites capable of infecting erythrocytes.
The circumsporozoite protein is considered to be the principal antigen on the surface of sporozoites. Epitopes found on this antigen react with antibodies that inhibit the invasion of hepatocytes by sporozoites and induce cellular responses that kill sporozoite-infected liver cells.2 Complete immunity against infection rarely develops from natural exposure, but immunization with radiation-attenuated sporozoites affords full protection.3 This vaccine strategy is not practical, since it requires repeated exposure to hundreds of infected, irradiated mosquitoes over a period of 6 to 10 months, and sporozoites cannot be cultured in vitro. Nonetheless, these findings revealed a critical role for the circumsporozoite protein in the development of immunity against sporozoite challenge and led to its development as a candidate vaccine.4,5 In clinical trials, however, the circumsporozoite protein is poorly immunogenic, and few subjects have been protected.6 To address these issues, we created a hybrid in which the circumsporozoite protein fused to hepatitis B surface antigen (HBsAg) was expressed together with unfused HBsAg. The resulting hybrid was significantly more potent than previous circumsporozoite-protein formulations.7 We hypothesized that more potent adjuvants could improve the efficacy of the vaccine. We therefore conducted a clinical trial to determine the safety and efficacy of three formulations of circumsporozoite-protein vaccines against P. falciparum.
Methods
Subjects
Forty-six subjects who had not been exposed to malaria (age, 18 to 45 years) were recruited by noncoercive means under a protocol approved by an institutional review board. Potential risks associated with participation in the study, including those associated with a malaria challenge, were discussed at the time of recruitment. Written informed consent was obtained from each subject before enrollment, and subjects were permitted to drop out of the study at any time without prejudice. Subjects were excluded if they had undergone splenectomy; had any cardiovascular, hepatic, or renal abnormalities; were allergic to any antimalarial drugs; were immunodeficient or pregnant; or had conditions that would increase the risk of an adverse outcome from malaria.
Study Design and Vaccines
We designed an open-label trial of three formulations of the vaccine RTS,S (SmithKline Beecham Biologicals, Rixensart, Belgium) with no placebo control. RTS,S consists of two polypeptides that spontaneously form composite particulate structures on their simultaneous synthesis in yeast (Saccharomyces cerevisiae). RTS is a single polypeptide chain corresponding to amino acids 207 to 395 of P. falciparum (3D7) that is fused to HBsAg (adw serotype). S is a polypeptide of 226 amino acids that corresponds to HBsAg. The particles were purified from yeast-cell cultures and constitute the antigen used in the formulations.
Vaccine 1 consisted of RTS,S in a formulation containing alum and monophosphoryl lipid A (designated SBAS4); vaccine 2 consisted of RTS,S in an oil-in-water emulsion (SBAS3); vaccine 3 consisted of RTS,S in this emulsion plus the immune stimulants monophosphoryl lipid A and QS21 (SBAS2). The standard dose of vaccine 1 was 1 ml, and that of vaccines 2 and 3 was 0.5 ml; each dose delivered 50 μg of RTS,S antigen. The third dose of vaccines 2 and 3 was reduced to 0.1 ml in response to adverse reactions after the second dose. Vaccines were administered intramuscularly in the deltoid region at 0, 4, and approximately 28 weeks (range, 25 to 28). All subjects who received three doses were asked to volunteer for sporozoite challenge.
Follow-up and Outcome Measures
The subjects were observed for 20 minutes after immunization and evaluated at 1, 2, 7, and 14 days. A reaction was graded as mild if it was easily tolerated, moderate if it interfered with normal activity, and severe if it prevented normal activity and required treatment. Blood was obtained for laboratory studies on the day of vaccination and 1 and 14 days later. Serum was separated and frozen at -70°C until use. Total IgG and IgG subclasses were measured by enzyme-linked immunosorbent assay (ELISA) with recombinant R32LR for antibodies against tandem-repeat epitopes and synthetic peptides for antibodies against the carboxy terminal.7 Quantitative measurements of IgG subclasses were performed with a modification of a murine ELISA.8 Standard curves were generated with human myeloma kappa-chain IgG1, IgG2, IgG3, and IgG4 (Binding Site, San Diego, Calif.), and the results were normalized against a human reference standard. Levels of antibodies against tandem-repeat epitopes were determined relative to a different circumsporozoite-specific standard; thus, sums of subclass values differ from the total IgG value determined by ELISA. Flanking-region antibody levels were reported in optical-density units, the dilution yielding an optical density of 1.000. Antibodies against HBsAg were measured by ELISA.9 Seroconversion was considered to have occurred if postimmunization antibody titers against circumsporozoite tandem-repeat epitopes exceeded the mean base-line values plus 2 SD. Serum samples were analyzed by an indirect fluorescence antibody assay with air-dried sporozoites.10
Peripheral-blood mononuclear cells were isolated from donor blood by gradient centrifugation on Ficoll and stored in liquid nitrogen until use. Proliferative and cytolytic assays were performed on cells obtained before immunization and after the third dose of vaccine. The cells were thawed, washed, diluted in culture medium, and dispensed into 96-well round-bottom plates. Purified recombinant antigens (RTS,S and HBsAg) and synthetic peptides from the carboxy-terminal nonrepeated amino acid sequences from the P. falciparum 3D7 circumsporozoite protein, including residues 317 to 360, 349 to 395, and 361 to 393, plus a putative universal helper T-cell epitope11 were used to stimulate the cells for seven days. Control cultures were stimulated with phytohemagglutinin (2 μg per milliliter), irrelevant control peptide, or medium alone. Proliferative responses were measured by the uptake of tritiated thymidine, and the results calculated as stimulation indexes.
Supernatants from parallel cultures were collected after 96 hours to measure interferon-γ by ELISA (Genzyme, Cambridge, Mass.). Serial dilutions (1:2, 1:4, 1:8, and so on) of a human interferon-γ standard were assayed in parallel, and concentrations calculated from the standard curve. Cytolytic T-cell studies were performed in a subgroup of six subjects selected for HLA class I types for which circumsporozoite epitopes are known; these include HLA-A2.1 (residues 331 to 350),12 HLA-B7 (residues 300 to 308),13 and HLA-B35 (residues 368 to 375).14 Quadruplicate cultures were stimulated with the HLA class I–restricted peptide for 7 or 14 days in the presence of recombinant interleukin-2. Standard chromium-release assays were performed with either autologous or HLA class I–matched B-cell blasts after transformation with the Epstein–Barr virus; the target cells were pulsed with the HLA class I–restricted peptides.
The vaccine was considered to be efficacious if there was no parasitologic evidence of P. falciparum infection after exposure to a sporozoite challenge that caused infection in 100 percent of unimmunized control subjects. Cloned chloroquine-sensitive P. falciparum 3D7 parasites were increased from a master seed lot and used to infect laboratory-reared Anopheles stephensi. Challenge15 occurred on one of three consecutive days approximately three weeks after the third dose of vaccine. Mosquitoes harvested from the same batch fed on a subject for five minutes, and those that had become engorged with blood were dissected to quantify the viable sporozoites. The challenge continued until five infected mosquitoes had successfully fed. On day 1, 12 subjects (7 given vaccine 1, 3 given vaccine 2, and 2 given vaccine 3) and 3 unimmunized controls were challenged. Nine subjects (one given vaccine 1 and four each given vaccine 2 and 3) and three other controls were challenged on the second day, and one subject given vaccine 3 was challenged on the third day. The sporozoite burdens in mosquito salivary glands were uniformly heavy throughout the challenge period.
The subjects were examined and blood was collected for smears each morning between days 7 and 21; blood was then obtained weekly for smears for the next three weeks. The subjects were followed monthly thereafter, and blood smears were examined for malaria if symptoms developed. Subjects who remained asymptomatic and parasite-free for 60 days after challenge were considered to be protected against the disease. Giemsa-stained thick smears were routinely examined for 200 high-power fields in the case of asymptomatic subjects and were reviewed exhaustively in the case of symptomatic subjects. The subjects who became infected were treated with an oral regimen of chloroquine plus other medications as indicated by their symptoms and were followed daily until three consecutive blood smears were negative for malaria and all symptoms had resolved.
Statistical Analysis
Statistical analyses were performed with a computerized statistical program. Comparisons of vaccine efficacy and the length of time to the onset of parasitemia were performed with Fisher's exact test and the log-rank test, respectively. The relative risks and their 95 percent confidence intervals were calculated. The immune responses of the three groups of subjects were compared with the Mann–Whitney test. All P values are two-tailed.
Results
Study Population
Forty-six subjects (mean age, 30.9 years) were enrolled and received at least one immunization. Fourteen subjects were randomly assigned to receive vaccine 1, 15 to receive vaccine 2, and 17 to receive vaccine 3. Five subjects assigned to receive vaccine 1 and five assigned to vaccine 2 were positive for HBsAg on entry into the study, as compared with nine subjects assigned to receive vaccine 3. Six men and 7 women received two doses of vaccine 1, 6 men and 9 women received two doses of vaccine 2, and 10 men and 3 women received two doses of vaccine 3. Twenty-seven subjects received a third dose, of whom 22 agreed to undergo sporozoite challenge. Among the subjects who did not receive three doses of vaccine, all but two did not complete the study because of problems with scheduling or noncompliance at required follow-up visits.
Safety
No clinically important abnormal laboratory values were detected after the administration of any dose. All initial doses were well tolerated, causing mild discomfort at the site of the injection. In contrast, the second doses of vaccines 2 and 3 produced more reactions. Four subjects had severe symptoms. In one of these, a subject with a history of migraines who received vaccine 3, an uncomplicated headache developed one week after the first dose. Three other subjects (two given vaccine 2 and one given vaccine 3) had constitutional symptoms, including pain, malaise, feverishness, headache, and myalgias, within 24 hours after receiving the second dose. Laboratory results were unremarkable and did not suggest a cause for their symptoms. We did not give the two subjects with the most symptoms (one given vaccine 2 and one given vaccine 3) a third dose, and we reduced the third dose to 0.1 ml for the remaining subjects assigned to receive vaccine 2 or 3. All third doses were well tolerated.
Immunogenicity
Antibodies against circumsporozoite tandem-repeat epitopes developed in all subjects who received two or more doses (Figure 1Figure 1
Geometric Mean Responses of Antibody against Circumsporozoite Tandem-Repeat Epitopes after the Administration of the Vaccines.). The levels peaked after the second dose, declined between the second and third doses, and then returned toward maximal levels after the third dose. There was considerable individual variability in antibody responses, and the small sample size precluded a meaningful analysis of the effect of preexisting hepatitis B immunity on antisporozoite responses. However, when considered as a group after two or three doses, the responses to vaccines 2 and 3 were significantly greater than those to vaccine 1 (P<0.02).In contrast, the responses to HBsAg were clearly affected by preexisting hepatitis B immunity. Whereas all subjects who were negative for HBsAg before immunization seroconverted after receiving a single dose of vaccine 2 or 3, most such subjects required two doses of vaccine 1 to seroconvert and three doses to achieve maximal responses. On the other hand, subjects who were positive for HBsAg before immunization had nearly maximal responses after the first dose, and subsequent doses resulted in minimal increases in the response. Mean HBsAg titers on ELISA after three doses of any formulation exceeded 105 mIU per milliliter, regardless of whether there was preexisting immunity to hepatitis B.
Vaccine Efficacy
Twenty-two subjects who received three doses of vaccine agreed to a challenge with P. falciparum sporozoites, eight given vaccine 1 and seven each given vaccines 2 and 3. Six unimmunized subjects served as controls, and parasitemia developed in all six 11 to 13 days after sporozoite challenge. Malaria developed in seven of eight subjects given vaccine 1, with a mean prepatent period of 12.6 days (range, 11 to 18). Five of seven subjects given vaccine 2 became infected, with a mean prepatent period of 15.2 days (range, 14 to 19). The length of time to the onset of malaria was significantly longer among those given vaccine 2 than among the controls (P<0.01 by the log-rank test). In contrast, only one of seven subjects given vaccine 3 became infected, for an estimated vaccine efficacy of 86 percent (relative risk of infection, 0.14; 95 percent confidence interval, 0.02 to 0.88; P<0.005). Subjects who were asymptomatic and parasite-free for 60 days after challenge remained so more than 6 months after challenge.
Protected subjects tended to have higher antibody titers against tandem-repeat epitopes than those in whom malaria developed, and the only subject given vaccine 3 who became infected had a poor antibody response (Table 1Table 1
Titers of Antibodies against Circumsporozoite Tandem-Repeat Epitopes and Intact Sporozoites at the Time of Sporozoite Challenge.). On the day of challenge, antibody titers against tandem-repeat epitopes measured by ELISA correlated well with indirect fluorescence antibody responses (coefficient of correlation, 0.86), indicating that these antibodies accounted for most of the reactivity against intact sporozoites. IgG1 and IgG2 accounted for nearly all the antibody against tandem-repeat epitopes, whereas IgG3 and IgG4 responses were minimal (data not shown). Antibodies against carboxy-terminal epitopes were more common and pronounced in subjects given vaccine 2 or 3, but the titers were not predictive of protection. Geometric mean antibody titers against tandem-repeat epitopes or intact sporozoites did not differ significantly between the groups receiving vaccine 2 or 3 who underwent sporozoite challenge (Table 2Table 2
Geometric Mean Sporozoite Antibody Levels among the Subjects Who Underwent Sporozoite Challenge.). After three doses, a majority of all subjects had evidence of immunologic priming to one or more RTS,S epitopes, as evidenced by proliferative responses or interferon-γ production in response to antigen stimulation, but the presence of circumsporozoite-specific cellular responses did not predict protection (data not shown).Among the small subgroup of subjects selected on the basis of HLA class I typing (four of whom were protected and two of whom were not), there was no clear evidence of cytolytic T-cell activity in cultures of peripheral-blood mononuclear cells obtained after immunization, as measured by lysis of peptide-labeled HLA class I–restricted target cells.
Discussion
We have developed an immunogenic recombinant circumsporozoite vaccine that protects adults who have never been exposed to malaria against experimental challenge with P. falciparum sporozoites. The process required more than a decade, during which our group and others have systematically evaluated numerous candidate formulations.6,16-24 Until now, the only strategy that predictably protected humans was immunization with irradiated sporozoites.25 This impractical model established the basis for current sporozoite vaccine strategies, including the identification of the circumsporozoite protein as a leading candidate vaccine.2,26 The RTS,S vaccine contains circumsporozoite-protein central tandem-repeat epitopes and carboxy-terminal epitopes that provide targets for both antibody and cellular responses. The tandem-repeat epitopes are highly conserved among P. falciparum isolates and are recognized by antibodies that neutralize the infectivity of sporozoites for liver cells.27 In preclinical adjuvant screening studies, the SBAS2 formulation (vaccine 3) proved superior for inducing strong antibody responses and strong antigen-specific delayed hypersensitivity in primates and proliferative and cytolytic T-cell responses in mice.
Pre-erythrocytic immunity is an all-or-none phenomenon, and experimental sporozoite challenge provides a powerful tool for screening vaccine candidates. The response is very clear, for if a single sporozoite completes its development in the liver, clinical malaria ensues. Plasmodia are superbly adapted to humans, and in the field, pre-erythrocytic immunity develops rarely if at all.28 This observation is consistent with the concept that certain pathogens or antigens are not recognized as dangerous by the immune system and fail to induce protective immune responses.29 Indeed, developing liver schizonts express abundant circumsporozoite protein, and except in the setting of hyperimmunization with attenuated sporozoites, schizont-infected hepatocytes fail to elicit inflammatory infiltrates.30
Our study demonstrated that strong adjuvants were required, but comparison of the efficacy of SBAS2 (vaccine 3) with that of SBAS3 (vaccine 2) suggested that strong antibody responses to tandem-repeat epitopes alone were insufficient to confer protection. Effective adjuvants such as those in SBAS2 may also provide signals required to up-regulate costimulatory molecules on antigen-presenting cells, induce expression of molecules that permit these cells to travel to target tissues, or induce production of cytokines that mediate protection.31
We have not yet identified the cellular mechanisms that explain the protection obtained with the SBAS2 formulation, but it might provide an optimal stimulus for T cells recruited after challenge to eliminate liver-stage parasites by enhanced local release of interferon-γ.32 The period between the administration of the reduced third dose of vaccine and sporozoite challenge was less than a month, but the absence of constitutional symptoms after immunization makes it unlikely that protection was mediated by nonspecific transiently circulating cytokines. Although cellular studies are incomplete, there is no evidence to date that the vaccine protected subjects through mechanisms involving cytolytic T cells. In the light of the proliferative responses or the production of interferon-γ in response to RTS,S epitopes in a number of subjects, the role of CD4+ T-cell responses must be further investigated.33
Many important questions remain to be addressed before the full potential of this vaccine is known. In particular, expanded safety studies will be needed and efficacy against heterologous challenge must be determined in the field. The history of humanity's struggle with this disease is a sobering reminder of the hard work that still lies ahead.
Supported in part by a grant (1893) from the Belgian Walloon Region and conducted under a Collaborative Research and Development Agreement (DAMD17-92-0624) between the Walter Reed Army Institute of Research and SmithKline Beecham Biologicals under the supervision of Drs. Ballou and Cohen, who served as the senior investigators for the project. The study was funded and conducted by the U.S. Army Medical Research and Development Command.
The views of the authors do not necessarily reflect the position of the Department of the Army or the Department of Defense.
We are indebted to Joe Williams, Eugene Watson, Carolyn Holland, Maxine McClain, Dr. Nelly Kolodny, Dr. Brian Hanson, Dr. Montip Ngampochana, Peifang Sun, Craig Hammond, Megan Dowler, Dr. Imogene Schneider, Dr. Moshe Schmuklarsky, and the staff of Walter Reed Army Institute of Research Clinical Trials Center; to Dr. Janet Wittes, Dr. Jolie Palensky, Dr. Glenn Wortmann, and Dr. Daniel Carruci; and to Dr. August J. Salvado, Jean Stephenne, Dr. Michel De Wilde, Dr. John Boslego, Dr. William H. Bancroft, and Mitchell Gross for their constant support and commitment to the success of this project.
Source Information
From the Walter Reed Army Institute of Research, Washington, D.C. (J.A.S., D.G.H., K.E.K., B.T.W., U.K., W.R.B.); and SmithKline Beecham Biologicals, Rixensart, Belgium (M.S., P.M., P.D., N.G., M.M., J.D.C.).
Address reprint requests to Dr. Ballou at the Department of Immunology, Walter Reed Army Institute of Research, Washington, DC 20307-5100.
The members of the RTS,S Malaria Vaccine Evaluation Group are listed in the Appendix.
Appendix
The following are members of the RTS,S Malaria Vaccine Evaluation Group: S. Biernaux, J.-P. Prieels, M. Van Handenhove, P. Voet, G. Ardesi, P. Roelants, and M. Comberbach, SmithKline Beecham Biologicals, Rixensart, Belgium; K. White, R. Schwenk, B.T. Hall, C.F. Ockenhouse, A. Magill, C. Golenda, R.A. Wirtz, G.M. Glenn, D.M. Gordon, and J.C. Sadoff, Walter Reed Army Institute of Research, Washington, D.C.; and T.P. Le, A. Malik, J. Sacci, T. de la Vega, and S.L. Hoffman, Naval Medical Research Institute, Bethesda, Md.
- References
References
1
World Health Organization 2
Rieckmann KH ,Carson PE ,Beaudoin RL ,Cassells JS ,Sell KW . Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans R Soc Trop Med Hyg 1974;68:258-259
CrossRef | Web of Science | Medline3
Nardin EH ,Nussenzweig V ,Nussenzweig RS , et al. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J Exp Med 1982;156:20-30
CrossRef | Web of Science | Medline4
Sinnis P, Nussenzweig V. Preventing sporozoite invasion of hepatocytes. In: Hoffman SL, ed. Malaria vaccine development: a multi-immune response approach. Washington, D.C.: ASM Press, 1996:15-33.
5
Nardin EH ,Nussenzweig RS . T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages. Annu Rev Immunol 1993;11:687-727
CrossRef | Web of Science | Medline6
Ballou WR. Progress in malaria vaccines. In: Cryz SJ Jr, ed. Vaccines and immunotherapy. Elmsford, N.Y.: Pergamon Press, 1991:373-80.
7
Gordon DM ,McGovern TW ,Krzych U , et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 1995;171:1576-1585
CrossRef | Web of Science | Medline8
Glenn GM ,Rao M ,Richards RL ,Matyas GR ,Alving CR . Murine IgG subclass antibodies to antigens incorporated in liposomes containing lipid A. Immunol Lett 1995;47:73-78
CrossRef | Web of Science | Medline9
Hollinger FB ,Troisi CL ,Pepe PE . Anti-HBs responses to vaccination with a human hepatitis B vaccine made by recombinant DNA technology in yeast. J Infect Dis 1986;153:156-159
CrossRef | Web of Science | Medline10
Wirtz RA ,Ballou WR ,Schneider I , et al. Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli. Exp Parasitol 1987;63:166-172
CrossRef | Web of Science | Medline11
Sinigaglia F ,Guttinger M ,Kilgus J , et al. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 1988;336:778-780
CrossRef | Web of Science | Medline12
Blum-Tirouvanziam U ,Servis C ,Habluetzel A , et al. Localization of HLA-A2.1-restricted T cell epitopes in the circumsporozoite protein of Plasmodium falciparum. J Immunol 1995;154:3922-3931
Web of Science | Medline13
Aidoo M ,Lalvani A ,Allsopp CE , et al. Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria. Lancet 1995;345:1003-1007
CrossRef | Web of Science | Medline14
Hill AVS ,Elvin J ,Willis AC , et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 1992;360:434-439
CrossRef | Web of Science | Medline15
Chulay JD ,Schneider I ,Cosgriff TM , et al. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg 1986;35:66-68
Web of Science | Medline16
Ballou WR ,Rothbard J ,Wirtz RA , et al. Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium falciparum. Science 1985;228:996-999
CrossRef | Web of Science | Medline17
Ballou WR ,Hoffman SL ,Sherwood JA , et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1987;1:1277-1281
CrossRef | Web of Science | Medline18
Herrington DA ,Clyde DF ,Losonsky G , et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 1987;328:257-259
CrossRef | Web of Science | Medline19
Ballou WR ,Young JF ,Cryz SJ ,Sadoff JC . The development of molecular vaccines against malaria sporozoites. Adv Exp Med Biol 1989;251:295-313
Web of Science | Medline20
Sherwood JA ,Oster CN ,Adoyo-Adoyo M , et al. Safety and immunogenicity of a Plasmodium falciparum sporozoite vaccine: boosting of antibody response in a population with prior natural exposure to malaria. Trans R Soc Trop Med Hyg 1991;85:336-340
CrossRef | Web of Science | Medline21
Brown AE ,Singharaj P ,Webster HK , et al. Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers. Vaccine 1994;12:102-108
CrossRef | Web of Science | Medline22
Hoffman SL ,Edelman R ,Bryan JP , et al. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant. Am J Trop Med Hyg 1994;51:603-612
Web of Science | Medline23
Rutgers T ,Gordon D ,Gathoye AM , et al. Hepatitis B surface antigen as carrier matrix for the repetitive epitope of the circumsporozoite protein of Plasmodium falciparum. Biotechnology 1988;6:1065-1070
CrossRef | Web of Science24
Vreden SG ,Verhave JP ,Oettinger T ,Sauerwein RW ,Meuwissen JH . Phase I clinical trial of a recombinant malaria vaccine consisting of the circumsporozoite repeat region of Plasmodium falciparum coupled to hepatitis B surface antigen. Am J Trop Med Hyg 1991;45:533-538
Web of Science | Medline25
Egan JE ,Hoffman SL ,Haynes JD , et al. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg 1993;49:166-173
Web of Science | Medline26
Nussenzweig V ,Nussenzweig RS . Rationale for the development ofan engineered sporozoite malaria vaccine. Adv Immunol 1989;45:283-334
CrossRef | Web of Science | Medline27
Hollingdale MR ,Nardin EH ,Tharavanij S ,Schwartz AL ,Nussenzweig RS . Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells: an in vitro assay of protective antibodies. J Immunol 1984;132:909-913
Web of Science | Medline28
Hoffman SL ,Oster CN ,Plowe CV , et al. Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science 1987;237:639-642
CrossRef | Web of Science | Medline29
Matzinger P . Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045
CrossRef | Web of Science | Medline30
Scheller LF ,Azad AF . Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc Natl Acad Sci U S A 1995;92:4066-4068
CrossRef | Web of Science | Medline31
Di Rosa F ,Matzinger P . Long-lasting CD8 T cell memory in the absence of CD4 T cells or B cells. J Exp Med 1996;183:2153-2163
CrossRef | Web of Science | Medline32
Schofield L ,Villaquiran J ,Ferreira A ,Schellekens H ,Nussenzweig RS ,Nussenzweig V . Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 1987;330:664-666
CrossRef | Web of Science | Medline33
Moreno A ,Clavijo P ,Edelman R , et al. CD4+ T cell clones obtained from Plasmodium falciparum sporozoite-immunized volunteers recognize polymorphic sequences of the circumsporozoite protein. J Immunol 1993;151:489-499
Web of Science | Medline
- Citing Articles (238)
Citing Articles
1
Mahamadou A. Thera, Christopher V. Plowe. (2012) Vaccines for Malaria: How Close Are We?. Annual Review of Medicine 63:1, 345-357
CrossRef2
D. Lys Guilbride, Patrick D.L. Guilbride, Pawel Gawlinski. (2012) Malaria's deadly secret: a skin stage. Trends in Parasitology
CrossRef3
Huaiyu Zhou, Juan Min, Qunli Zhao, Qinmin Gu, Hua Cong, Ying Li, Shenyi He. (2012) Protective immune response against Toxoplasma gondii elicited by a recombinant DNA vaccine with a novel genetic adjuvant. Vaccine
CrossRef4
Jean-Pierre Amorij, Gideon F.A. Kersten, Vinay Saluja, Wouter F. Tonnis, Wouter L.J. Hinrichs, Bram Slütter, Suzanne M. Bal, Joke A. Bouwstra, Anke Huckriede, Wim Jiskoot. (2012) Towards tailored vaccine delivery: needs, challenges and perspectives. Journal of Controlled Release
CrossRef5
Wai-Hong Tham, Julie Healer, Alan F. Cowman. (2011) Erythrocyte and reticulocyte binding-like proteins of Plasmodium falciparum. Trends in Parasitology
CrossRef6
A. V. S. Hill. (2011) Vaccines against malaria. Philosophical Transactions of the Royal Society B: Biological Sciences 366:1579, 2806-2814
CrossRef7
Xinyuan Chen, Mei X Wu. (2011) Laser vaccine adjuvant for cutaneous immunization. Expert Review of Vaccines 10:10, 1397-1403
CrossRef8
Thera, Mahamadou A., Doumbo, Ogobara K., Coulibaly, Drissa, Laurens, Matthew B., Ouattara, Amed, Kone, Abdoulaye K., Guindo, Ando B., Traore, Karim, Traore, Idrissa, Kouriba, Bourema, Diallo, Dapa A., Diarra, Issa, Daou, Modibo, Dolo, Amagana, Tolo, Youssouf, Sissoko, Mahamadou S., Niangaly, Amadou, Sissoko, Mady, Takala-Harrison, Shannon, Lyke, Kirsten E., Wu, Yukun, Blackwelder, William C., Godeaux, Olivier, Vekemans, Johan, Dubois, Marie-Claude, Ballou, W. Ripley, Cohen, Joe, Thompson, Darby, Dube, Tina, Soisson, Lorraine, Diggs, Carter L., House, Brent, Lanar, David E., Dutta, Sheetij, Heppner, D. Gray Jr., Plowe, Christopher V., . (2011) A Field Trial to Assess a Blood-Stage Malaria Vaccine. New England Journal of Medicine 365:11, 1004-1013
Full Text9
Nirianne Marie Q. Palacpac, Nobuko Arisue, Takahiro Tougan, Ken J. Ishii, Toshihiro Horii. (2011) Plasmodium falciparum serine repeat antigen 5 (SE36) as a malaria vaccine candidate. Vaccine 29:35, 5837-5845
CrossRef10
Pedro Aide, Carlota Dobaño, Jahit Sacarlal, John J. Aponte, Inácio Mandomando, Caterina Guinovart, Quique Bassat, Montse Renom, Laura Puyol, Eusebio Macete, Esperanza Herreros, Amanda Leach, Marie-Claude Dubois, Marie-Ange Demoitie, Marc Lievens, Johan Vekemans, Christian Loucq, W. Ripley Ballou, Joe Cohen, Pedro L. Alonso. (2011) Four year immunogenicity of the RTS,S/AS02A malaria vaccine in Mozambican children during a phase IIb trial. Vaccine 29:35, 6059-6067
CrossRef11
Robert J. Schwenk, Thomas L. Richie. (2011) Protective immunity to pre-erythrocytic stage malaria. Trends in Parasitology 27:7, 306-314
CrossRef12
Rino Rappuoli, Alan Aderem. (2011) A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 473:7348, 463-469
CrossRef13
Christopher Chang. (2011) Cutting Edge Issues in Rheumatic Fever. Clinical Reviews in Allergy & Immunology
CrossRef14
Jason A Regules, James F Cummings, Christian F Ockenhouse. (2011) The RTS,S vaccine candidate for malaria. Expert Review of Vaccines 10:5, 589-599
CrossRef15
Nathalie Garçon, Marcelle Van Mechelen. (2011) Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems. Expert Review of Vaccines 10:4, 471-486
CrossRef16
Christopher Palma, Michael G. Overstreet, Jean-Marc Guedon, Egbert Hoiczyk, Cameron Ward, Kasey A. Karen, Fidel Zavala, Gary Ketner. (2011) Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice. Vaccine 29:8, 1683-1689
CrossRef17
Robert W. Sauerwein, Meta Roestenberg, Vasee S. Moorthy. (2011) Experimental human challenge infections can accelerate clinical malaria vaccine development. Nature Reviews Immunology 11:1, 57-64
CrossRef18
Keith Limbach, Joao Aguiar, Kalpana Gowda, Noelle Patterson, Esteban Abot, Martha Sedegah, John Sacci, Thomas Richie. (2011) Identification of two new protective pre-erythrocytic malaria vaccine antigen candidates. Malaria Journal 10:1, 65
CrossRef19
Peter D. Crompton, Susan K. Pierce, Louis H. Miller. (2010) Advances and challenges in malaria vaccine development. Journal of Clinical Investigation 120:12, 4168-4178
CrossRef20
J. Cohen, S. Benns, J. Vekemans, A. Leach. (2010) Le candidat vaccin antipaludique RTS,S/AS est entré en essais cliniques de phase III. Annales Pharmaceutiques Françaises 68:6, 370-379
CrossRef21
Isabel Leroux-Roels, Marguerite Koutsoukos, Frédéric Clement, Sophia Steyaert, Michel Janssens, Patricia Bourguignon, Kristen Cohen, Marcus Altfeld, Pierre Vandepapelière, Louise Pedneault, Lisa McNally, Geert Leroux-Roels, Gerald Voss. (2010) Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems. Vaccine 28:43, 7016-7024
CrossRef22
Blaise Genton, Valérie D’Acremont, Floriana Lurati-Ruiz, Daniele Verhage, Régine Audran, Cornelus Hermsen, Liselotte Wolters, Christophe Reymond, François Spertini, Robert Sauerwein. (2010) Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum. Vaccine 28:40, 6573-6580
CrossRef23
Geert Leroux-Roels. (2010) Unmet needs in modern vaccinology. Vaccine 28, C25-C36
CrossRef24
Sofia Casares, Teodor-Doru Brumeanu, Thomas L. Richie. (2010) The RTS,S malaria vaccine. Vaccine 28:31, 4880-4894
CrossRef25
Joseph R. Fitchett, Mary K. Cooke. (2010) Genetically engineered parasites: the solution to designing an effective malaria vaccine?. Trends in Parasitology 26:7, 322-323
CrossRef26
Cristina T. Stoyanov, Silvia B. Boscardin, Stephanie Deroubaix, Giovanna Barba-Spaeth, David Franco, Ruth S. Nussenzweig, Michel Nussenzweig, Charles M. Rice. (2010) Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoelii. Vaccine 28:29, 4644-4652
CrossRef27
Claudia A Daubenberger. (2010) Gene-expression analysis for prediction of RTS,S-induced protection in humans. Expert Review of Vaccines 9:5, 465-469
CrossRef28
Giuseppe Del Giudice, Rino Rappuoli. 2010. Adjuvants and Subunit Vaccines. .
CrossRef29
Vasee S Moorthy, Marie Paule Kieny. (2010) Reducing empiricism in malaria vaccine design. The Lancet Infectious Diseases 10:3, 204-211
CrossRef30
Giampietro Corradin, Andrey V Kajava. (2010) Malaria vaccine: why is it taking so long?. Expert Review of Vaccines 9:2, 111-114
CrossRef31
Christian Loucq. (2010) Malaria vaccines: current situation, challenges and strategy for the future; a developer’s perspective from the PATH Malaria Vaccine Initiative. Therapy 7:1, 59-67
CrossRef32
Karen G. Heal, Andrew W. Taylor-Robinson. (2010) Tomatine Adjuvantation of Protective Immunity to a Major Pre-erythrocytic Vaccine Candidate of Malaria is Mediated via CD8+ T Cell Release of IFN-γ. Journal of Biomedicine and Biotechnology 2010, 1-8
CrossRef33
S. Pichyangkul, P. Tongtawe, U. Kum-Arb, K. Yongvanitchit, M. Gettayacamin, M.R. Hollingdale, A. Limsalakpetch, V.A. Stewart, D.E. Lanar, S. Dutta, E. Angov, L.A. Ware, E.S. Bergmann-Leitner, B. House, G. Voss, M.C. Dubois, J.D. Cohen, M.M. Fukuda, D.G. Heppner, R.S. Miller. (2009) Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys. Vaccine 28:2, 452-462
CrossRef34
Johan Vekemans, Amanda Leach, Joe Cohen. (2009) Development of the RTS,S/AS malaria candidate vaccine. Vaccine 27, G67-G71
CrossRef35
Ruobing Wang, Joseph D. Smith, Stefan H.I. Kappe. (2009) Advances and challenges in malaria vaccine development. Expert Reviews in Molecular Medicine 11,
CrossRef36
W. R. BALLOU. (2009) The development of the RTS,S malaria vaccine candidate: challenges and lessons. Parasite Immunology 31:9, 492-500
CrossRef37
R. N. COLER, D. CARTER, M. FRIEDE, S. G. REED. (2009) Adjuvants for malaria vaccines. Parasite Immunology 31:9, 520-528
CrossRef38
V.S. Moorthy, C. Diggs, S. Ferro, M.F. Good, S. Herrera, A.V. Hill, E.B. Imoukhuede, S. Kumar, C. Loucq, K. Marsh, C.F. Ockenhouse, T.L. Richie, R.W. Sauerwein. (2009) Report of a Consultation on the Optimization of Clinical Challenge Trials for Evaluation of Candidate Blood Stage Malaria Vaccines, 18–19 March 2009, Bethesda, MD, USA. Vaccine 27:42, 5719-5725
CrossRef39
V. ANN STEWART, R. COPPEL. (2009) Issues in malaria vaccine development. Parasite Immunology 31:9, 489-491
CrossRef40
Charlotte Schubert. (2009) Boosting our best shot. Nature Medicine 15:9, 984-988
CrossRef41
Michael F. Good. (2009) The hope but challenge for developing a vaccine that might control malaria. European Journal of Immunology 39:4, 939-943
CrossRef42
Gloria Gonzalez-Aseguinolaza. (2009) Malaria vaccine: the latest news from RTS,S/AS01E vaccine. Expert Review of Vaccines 8:3, 285-288
CrossRef43
Brian A. Bell, James F. Wood, Reeta Bansal, Hatem Ragab, John Cargo, Michael A. Washington, Chloe L. Wood, Lisa A. Ware, Christian F. Ockenhouse, Anjali Yadava. (2009) Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax. Vaccine 27:9, 1448-1453
CrossRef44
Jackeline F. Romero, Annalisa Ciabattini, Philippe Guillaume, Geraldine Frank, Paolo Ruggiero, Elena Pettini, Giuseppe Del Giudice, Donata Medaglini, Giampietro Corradin. (2009) Intranasal administration of the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei with the modified heat-labile toxin of Escherichia coli (LTK63) induces a complete protection against malaria challenge. Vaccine 27:8, 1266-1271
CrossRef45
Jerome P. Vanderberg. (2009) Reflections on early malaria vaccine studies, the first successful human malaria vaccination, and beyond. Vaccine 27:1, 2-9
CrossRef46
Steven G. Reed, Sylvie Bertholet, Rhea N. Coler, Martin Friede. (2009) New horizons in adjuvants for vaccine development. Trends in Immunology 30:1, 23-32
CrossRef47
Silayuv E. Bongfen, Patricia M. Ntsama, Sandra Offner, Thomas Smith, Ingrid Felger, Marcel Tanner, Pedro Alonso, Issa Nebie, Jackeline F. Romero, Olivier Silvie, Ralph Torgler, Giampietro Corradin. (2009) The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity. Vaccine 27:2, 328-335
CrossRef48
Abdulla, Salim, Oberholzer, Rolf, Juma, Omar, Kubhoja, Sulende, Machera, Francisca, Membi, Christopher, Omari, Said, Urassa, Alwisa, Mshinda, Hassan, Jumanne, Ajuza, Salim, Nahya, Shomari, Mwanjaa, Aebi, Thomas, Schellenberg, David M., Carter, Terrell, Villafana, Tonya, Demoitié, Marie-Ange, Dubois, Marie-Claude, Leach, Amanda, Lievens, Marc, Vekemans, Johan, Cohen, Joe, Ballou, W. Ripley, Tanner, Marcel, . (2008) Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants. New England Journal of Medicine 359:24, 2533-2544
Full Text49
Collins, William E., Barnwell, John W., . (2008) A Hopeful Beginning for Malaria Vaccines. New England Journal of Medicine 359:24, 2599-2601
Full Text50
Adriana Bermúdez, Magnolia Vanegas, Manuel Elkin Patarroyo. (2008) Structural and immunological analysis of circumsporozoite protein peptides: A further step in the identification of potential components of a minimal subunit-based, chemically synthesised antimalarial vaccine. Vaccine 26:52, 6908-6918
CrossRef51
Maria Katsara, Gabriela Minigo, Magdalena Plebanski, Vasso Apostolopoulos. (2008) The good, the bad and the ugly: how altered peptide ligands modulate immunity. Expert Opinion on Biological Therapy 8:12, 1873-1884
CrossRef52
Magdalena Plebanski, Emily Locke, James W. Kazura, Ross L. Coppel. (2008) Malaria vaccines: into a mirror, darkly?. Trends in Parasitology 24:12, 532-536
CrossRef53
Blaise Genton. (2008) Malaria vaccines: a toy for travelers or a tool for eradication?. Expert Review of Vaccines 7:5, 597-611
CrossRef54
Joseph P. Shott, Shannon M. McGrath, Maria Grazia Pau, Jerome H.V. Custers, Olga Ophorst, Marie-Ange Demoitié, Marie-Claude Dubois, Jack Komisar, Michelle Cobb, Kent E. Kester, Patrice Dubois, Joe Cohen, Jaap Goudsmit, D. Gray Heppner, V. Ann Stewart. (2008) Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-γ and antibody responses in mice. Vaccine 26:23, 2818-2823
CrossRef55
Rajeev K Tyagi, Pradeep Kumar Sharma, Suresh P Vyas, Abhinav Mehta. (2008) Various carrier system(s)- mediated genetic vaccination strategies against malaria - Retracted. Expert Review of Vaccines 7:4, 499-520
CrossRef56
Claudia A Daubenberger, Gerd Pluschke, Rinaldo Zurbriggen, Nicole Westerfeld. (2008) Development of influenza virosome-based synthetic malaria vaccines. Expert Opinion on Drug Discovery 3:4, 415-423
CrossRef57
Brian M. Greenwood, David A. Fidock, Dennis E. Kyle, Stefan H.I. Kappe, Pedro L. Alonso, Frank H. Collins, Patrick E. Duffy. (2008) Malaria: progress, perils, and prospects for eradication. Journal of Clinical Investigation 118:4, 1266-1276
CrossRef58
Alberto Pinzon-Charry, Michael F Good. (2008) Malaria vaccines: the case for a whole-organism approach. Expert Opinion on Biological Therapy 8:4, 441-448
CrossRef59
Kent E. Kester, James F. Cummings, Christian F. Ockenhouse, Robin Nielsen, B. Ted Hall, Daniel M. Gordon, Robert J. Schwenk, Urszula Krzych, Carolyn A. Holland, Gregory Richmond, Megan G. Dowler, Jackie Williams, Robert A. Wirtz, Nadia Tornieporth, Laurence Vigneron, Martine Delchambre, Marie-Ange Demoitie, W. Ripley Ballou, Joe Cohen, D. Gray Heppner. (2008) Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research. Vaccine 26:18, 2191-2202
CrossRef60
S. Phogat, K. Svehla, M. Tang, A. Spadaccini, J. Muller, J. Mascola, I. Berkower, R. Wyatt. (2008) Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles. Virology 373:1, 72-84
CrossRef61
Johan Vekemans, W Ripley Ballou. (2008) Plasmodium falciparum malaria vaccines in development. Expert Review of Vaccines 7:2, 223-240
CrossRef62
Pierre Vandepapelière, Yves Horsmans, Philippe Moris, Marcelle Van Mechelen, Michel Janssens, Marguerite Koutsoukos, Pascale Van Belle, Frédéric Clement, Emmanuel Hanon, Martine Wettendorff, Nathalie Garçon, Geert Leroux-Roels. (2008) Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 26:10, 1375-1386
CrossRef63
Pascal Mettens, Patrice M. Dubois, Marie-Ange Demoitié, Babak Bayat, Marie-Noëlle Donner, Patricia Bourguignon, V. Ann Stewart, D. Gray Heppner, Nathalie Garçon, Joe Cohen. (2008) Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen. Vaccine 26:8, 1072-1082
CrossRef64
Jahit Sacarlal, John J. Aponte, Pedro Aide, Inácio Mandomando, Quique Bassat, Caterina Guinovart, Amanda Leach, Jessica Milman, Eusebio Macete, Mateu Espasa, Opokua Ofori-Anyinam, Joelle Thonnard, Sabine Corachan, Marie-Claude Dubois, Marc Lievens, Filip Dubovsky, W. Ripley Ballou, Joe Cohen, Pedro L. Alonso. (2008) Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial. Vaccine 26:2, 174-184
CrossRef65
S XIAO, B ZHAN, J XUE, G GOUD, A LOUKAS, Y LIU, A WILLIAMSON, S LIU, V DEUMIC, P HOTEZ. (2008) The evaluation of recombinant hookworm antigens as vaccines in hamsters (Mesocricetus auratus) challenged with human hookworm, Necator americanus. Experimental Parasitology 118:1, 32-40
CrossRef66
Jiraprapa Wipasa, Eleanor M Riley. (2007) The immunological challenges of malaria vaccine development. Expert Opinion on Biological Therapy 7:12, 1841-1852
CrossRef67
Judith E Epstein. (2007) What will a partly protective malaria vaccine mean to mothers in Africa?. The Lancet 370:9598, 1523-1524
CrossRef68
John J Aponte, Pedro Aide, Montse Renom, Inacio Mandomando, Quique Bassat, Jahit Sacarlal, M Nelia Manaca, Sarah Lafuente, Arnoldo Barbosa, Amanda Leach, Marc Lievens, Johan Vekemans, Betuel Sigauque, Marie-Claude Dubois, Marie-Ange Demoitié, Marla Sillman, Barbara Savarese, John G McNeil, Eusebio Macete, W Ripley Ballou, Joe Cohen, Pedro L Alonso. (2007) Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. The Lancet 370:9598, 1543-1551
CrossRef69
Susann Szmania, Sacha Gnjatic, Guido Tricot, Katie Stone, Fenghuang Zhan, Amberly Moreno, Brad Thuro, Jos Melenhorst, John Barrett, John Shaughnessy, Lloyd J. Old, Bart Barlogie, Vincent G. Brichard, Frits van Rhee. (2007) Immunization With a Recombinant MAGE-A3 Protein After High-dose Therapy for Myeloma. Journal of Immunotherapy 30:8, 847-854
CrossRef70
Nathalie Garçon, Patrick Chomez, Marcelle Van Mechelen. (2007) GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Review of Vaccines 6:5, 723-739
CrossRef71
Sebastian A Mikolajczak, Ahmed SI Aly, Stefan HI Kappe. (2007) Preerythrocytic malaria vaccine development. Current Opinion in Infectious Diseases 20:5, 461-466
CrossRef72
Kai Matuschewski, Ann-Kristin Mueller. (2007) Vaccines against malaria ? an update. FEBS Journal 274:18, 4680-4687
CrossRef73
Pierre Druilhe, John W Barnwell. (2007) Pre-erythrocytic stage malaria vaccines: time for a change in path. Current Opinion in Microbiology 10:4, 371-378
CrossRef74
Olga J.A.E. Ophorst, Katarina Radošević, Jaco M. Klap, Jeroen Sijtsma, Gert Gillissen, Ratna Mintardjo, Mark J.M. van Ooij, Lennart Holterman, Arjen Companjen, Jaap Goudsmit, Menzo J.E. Havenga. (2007) Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant. Vaccine 25:35, 6501-6510
CrossRef75
Gabriela Minigo, Karen Scalzo, Katie L. Flanagan, Magdalena Plebanski. (2007) Predicting memory: a prospective readout for malaria vaccines?. Trends in Parasitology 23:8, 341-343
CrossRef76
Kent E. Kester, Denise A. McKinney, Nadia Tornieporth, Christian F. Ockenhouse, D. Gray Heppner, Ted Hall, Bruce T. Wellde, Kate White, Peifang Sun, Robert Schwenk, Urszula Krzych, Martine Delchambre, Gerald Voss, Marie-Claude Dubois, Robert A. Gasser, Megan G. Dowler, Megan O’Brien, Janet Wittes, Robert Wirtz, Joe Cohen, W. Ripley Ballou. (2007) A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults. Vaccine 25:29, 5359-5366
CrossRef77
Vasee Moorthy, Zarifah Reed, Peter G. Smith. (2007) Measurement of malaria vaccine efficacy in phase III trials: Report of a WHO consultation. Vaccine 25:28, 5115-5123
CrossRef78
D. Gray Heppner, Robert J. Schwenk, David Arnot, Robert W. Sauerwein, Adrian J.F. Luty. (2007) The dog that did not bark: malaria vaccines without antibodies. Trends in Parasitology 23:7, 293-296
CrossRef79
Mark E. Polhemus, Alan J. Magill, James F. Cummings, Kent E. Kester, Chris F. Ockenhouse, David E. Lanar, Sheetij Dutta, Arnoldo Barbosa, Lorraine Soisson, Carter L. Diggs, Sally A. Robinson, John D. Haynes, V. Ann Stewart, Lisa A. Ware, Clara Brando, Urszula Krzych, Robert A. Bowden, Joe D. Cohen, Marie-Claude Dubois, Opokua Ofori-Anyinam, Els De-Kock, W. Ripley Ballou, D. Gray Heppner. (2007) Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research. Vaccine 25:21, 4203-4212
CrossRef80
G. Moorthy, R. Ramasamy. (2007) Mucosal immunisation of mice with malaria protein on lactic acid bacterial cell walls. Vaccine 25:18, 3636-3645
CrossRef81
Anamika Khajuria, Amit Gupta, Surjeet Singh, Fayaz Malik, Jaswant Singh, K.A. Suri, N.K. Satti, G.N. Qazi, V.K. Srinivas, Gopinathan, Krishna Ella. (2007) RLJ-NE-299A: A new plant based vaccine adjuvant. Vaccine 25:14, 2706-2715
CrossRef82
L.E. Parra, G.P. Borja-Cabrera, F.N. Santos, L.O.P. Souza, C.B. Palatnik-de-Sousa, I. Menz. (2007) Safety trial using the Leishmune® vaccine against canine visceral leishmaniasis in Brazil. Vaccine 25:12, 2180-2186
CrossRef83
Zhi-Gang Yang, Yi-Ping Ye, Hong-Xiang Sun. (2007) Immunological Adjuvant Effect of Ginsenoside Rh4 from the Roots ofPanax notoginseng on Specific Antibody and Cellular Response to Ovalbumin in Mice. Chemistry & Biodiversity 4:2, 232-240
CrossRef84
E. Macete, J. J. Aponte, C. Guinovart, J. Sacarlal, O. Ofori-Anyinam, I. Mandomando, M. Espasa, C. Bevilacqua, A. Leach, M. C. Dubois, D. G. Heppner, L. Tello, J. Milman, J. Cohen, F. Dubovsky, N. Tornieporth, R. Thompson, P. L. Alonso. (2006) Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1?4 in Mozambique. Tropical Medicine and International Health 0:0, 061030012640005-???
CrossRef85
Patricia M Graves, Hellen Gelband, Patricia M Graves. 2006. Vaccines for preventing malaria. .
CrossRef86
Nicole Westerfeld, Gerd Pluschke, Rinaldo Zurbriggen. (2006) Optimized Malaria-antigens delivered by immunostimulating reconstituted influenza virosomes. Wiener klinische Wochenschrift 118:S3, 50-57
CrossRef87
Feng Qin, Yi-Ping Ye, Hong-Xiang Sun. (2006) Haemolytic Activity and Adjuvant Effect of Notoginsenoside K from the Roots ofPanax notoginseng. Chemistry & Biodiversity 3:10, 1144-1152
CrossRef88
T. RICHIE. (2006) High road, low road? Choices and challenges on the pathway to a malaria vaccine. Parasitology 133:S2, S113
CrossRef89
Kalifa A Bojang. (2006) RTS,S/AS02A for malaria. Expert Review of Vaccines 5:5, 611-615
CrossRef90
V. Ann Stewart, Douglas S. Walsh, Shannon M. McGrath, Kent E. Kester, James F. Cummings, Gerald Voss, Martine Delchambre, Nathalie Garçon, Joe D. Cohen, D. Gray Heppner. (2006) Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques. Vaccine 24:42-43, 6493-6502
CrossRef91
V. Ann Stewart, Shannon M. McGrath, Douglas S. Walsh, Stacey Davis, Aaron S. Hess, Lisa A. Ware, Kent E. Kester, James F. Cummings, J. Robert Burge, Gerald Voss, Martine Delchambre, Nathalie Garçon, Douglas B. Tang, Joe D. Cohen, D. Gray Heppner. (2006) Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. Vaccine 24:42-43, 6483-6492
CrossRef92
Magdalena Plebanski, Ester Lopez, Owen Proudfoot, Brian M. Cooke, Mark von Itzstein, Ross L. Coppel. (2006) Economic and practical challenges to the formulation of vaccines against endemic infectious diseases such as malaria. Methods 40:1, 77-85
CrossRef93
Kai Matuschewski. (2006) Vaccine development against malaria. Current Opinion in Immunology 18:4, 449-457
CrossRef94
Hong-Xiang Sun, Yuehua Chen, Yiping Ye. (2006) Ginsenoside Re and Notoginsenoside R1: Immunologic Adjuvants with Low Haemolytic Effect. Chemistry & Biodiversity 3:7, 718-726
CrossRef95
Pramatha R. Bhattacharya, Vinay Bhatia, C.R. Pillai. (2006) Genetic diversity of T-helper cell epitopic regions of circumsporozoite protein of Plasmodium falciparum isolates from India. Transactions of the Royal Society of Tropical Medicine and Hygiene 100:5, 395-400
CrossRef96
Hong-Xiang Sun, Hang-Jun Pan. (2006) Immunological adjuvant effect of Glycyrrhiza uralensis saponins on the immune responses to ovalbumin in mice. Vaccine 24:11, 1914-1920
CrossRef97
Vinay Bhatia, Pramatha R. Bhattacharya. (2006) Wild isolates of Plasmodium falciparum from India show restricted polymorphism in T-helper cell epitopes of the circumsporozoite protein. Acta Tropica 97:3, 259-264
CrossRef98
Michael Walther. (2006) Advances in vaccine development against the pre-erythrocytic stage of Plasmodium falciparum malaria. Expert Review of Vaccines 5:1, 81-93
CrossRef99
Hongxiang Sun, Zhigang Yang, Yiping Ye. (2006) Structure and biological activity of protopanaxatriol-type saponins from the roots of Panax notoginseng. International Immunopharmacology 6:1, 14-25
CrossRef100
J. C. R. HAFALLA, I. A. COCKBURN, F. ZAVALA. (2006) Protective and pathogenic roles of CD8+ T cells during malaria infection. Parasite Immunology 28:1-2, 15-24
CrossRef101
Adrian V. S. Hill. (2006) Pre-erythrocytic malaria vaccines: towards greater efficacy. Nature Reviews Immunology 6:1, 21-32
CrossRef102
Hong-Xiang Sun, Feng Qin, Yi-Ping Ye. (2005) Relationship between haemolytic and adjuvant activity and structure of protopanaxadiol-type saponins from the roots of Panax notoginseng. Vaccine 23:48-49, 5533-5542
CrossRef103
Hongxiang Sun, Quanfang Zheng. (2005) Haemolytic activities and adjuvant effect ofGynostemma pentaphyllum saponins on the immune responses to ovalbumin in mice. Phytotherapy Research 19:10, 895-900
CrossRef104
Ivette Caro-Aguilar, Stacey Lapp, Jan Pohl, Mary R. Galinski, Alberto Moreno. (2005) Chimeric epitopes delivered by polymeric synthetic linear peptides induce protective immunity to malaria. Microbes and Infection 7:13, 1324-1337
CrossRef105
Zhi-Gang Yang, Hong-Xiang Sun, Wei-Huan Fang. (2005) Haemolytic activities and adjuvant effect of Astragalus membranaceus saponins (AMS) on the immune responses to ovalbumin in mice. Vaccine 23:44, 5196-5203
CrossRef106
Brian Greenwood. (2005) Malaria vaccines. Acta Tropica 95:3, 298-304
CrossRef107
Jan A.M. Langermans, Annette Schmidt, Richard A.W. Vervenne, Ashley J. Birkett, J. Mauricio Calvo-Calle, Meike Hensmann, George B. Thornton, Filip Dubovsky, Horst Weiler, Elizabeth Nardin, Alan W. Thomas. (2005) Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques. Vaccine 23:41, 4935-4943
CrossRef108
W Ripley Ballou. (2005) Malaria vaccines in development. Expert Opinion on Emerging Drugs 10:3, 489-503
CrossRef109
Kalifa A. Bojang, Folasade Olodude, Margaret Pinder, Opokua Ofori-Anyinam, Laurence Vigneron, Steve Fitzpatrick, Fanta Njie, Adams Kassanga, Amanda Leach, Jessica Milman, Regina Rabinovich, Keith P.W.J. McAdam, Kent E. Kester, D. Gray Heppner, Joe D. Cohen, Nadia Tornieporth, Paul J.M. Milligan. (2005) Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine 23:32, 4148-4157
CrossRef110
Allan Saul. (2005) Models of Phase 1 vaccine trials: optimization of trial design to minimize risks of multiple serious adverse events. Vaccine 23:23, 3068-3075
CrossRef111
Pierre Vandepapelière, Barbara Rehermann, Marguerite Koutsoukos, Philippe Moris, Nathalie Garçon, Martine Wettendorff, Geert Leroux-Roels. (2005) Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults. Vaccine 23:20, 2591-2601
CrossRef112
Jan A.M. Langermans, T. Mark Doherty, Richard A.W. Vervenne, Tridia van der Laan, Konstantin Lyashchenko, Rena Greenwald, Else Marie Agger, Claus Aagaard, Horst Weiler, Dick van Soolingen, Wilfried Dalemans, Alan W. Thomas, Peter Andersen. (2005) Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23:21, 2740-2750
CrossRef113
Brian M Greenwood, Kalifa Bojang, Christopher JM Whitty, Geoffrey AT Targett. (2005) Malaria. The Lancet 365:9469, 1487-1498
CrossRef114
Bernadete Pereira da Silva, Juliana Baptista Rocha Correa Soares, Edilma Paraguai de Souza, Marcos Palatnik, Clarisa Beatriz Palatnik de Sousa, José Paz Parente. (2005) Pulcherrimasaponin, from the leaves of Calliandra pulcherrima, as adjuvant for immunization in the murine model of visceral leishmaniasis. Vaccine 23:8, 1061-1071
CrossRef115
Alex Loukas, Jeffrey M. Bethony, Susana Mendez, Ricardo T. Fujiwara, Gaddam Narsa Goud, Najju Ranjit, Bin Zhan, Karen Jones, Maria Elena Bottazzi, Peter J. Hotez. (2005) Vaccination with Recombinant Aspartic Hemoglobinase Reduces Parasite Load and Blood Loss after Hookworm Infection in Dogs. PLoS Medicine 2:10, e295
CrossRef116
Sócrates Herrera, Anilza Bonelo, Blanca Liliana Perlaza, Anais Zully Valencia, Catherine Cifuentes, Silvia Hurtado, Gustavo Quintero, José Alejandro López, Giampietro Corradin, Myriam Arévalo-Herrera. (2004) Use of long synthetic peptides to study the antigenicity and immunogenicity of the Plasmodium vivax circumsporozoite protein. International Journal for Parasitology 34:13-14, 1535-1546
CrossRef117
Siske S. Struik, Eleanor M. Riley. (2004) Does malaria suffer from lack of memory?. Immunological Reviews 201:1, 268-290
CrossRef118
Roberta L Richards, Mangala Rao, Thomas C Vancott, Gary R Matyas, Deborah L Birx, Carl R Alving. (2004) Liposome-stabilized oil-in-water emulsions as adjuvants: Increased emulsion stability promotes induction of cytotoxic T lymphocytes against an HIV envelope antigen. Immunology and Cell Biology 82:5, 531-538
CrossRef119
Pedro L Alonso, Jahit Sacarlal, John J Aponte, Amanda Leach, Eusebio Macete, Jessica Milman, Inacio Mandomando, Bart Spiessens, Caterina Guinovart, Mateu Espasa, Quique Bassat, Pedro Aide, Opokua Ofori-Anyinam, Margarita M Navia, Sabine Corachan, Marc Ceuppens, Marie-Claude Dubois, Marie-Ange Demoitié, Filip Dubovsky, Clara Menéndez, Nadia Tornieporth, W Ripley Ballou, Ricardo Thompson, Joe Cohen. (2004) Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. The Lancet 364:9443, 1411-1420
CrossRef120
Kota Arun Kumar, Giane A. Oliveira, Robert Edelman, Elizabeth Nardin, Victor Nussenzweig. (2004) Quantitative Plasmodium sporozoite neutralization assay (TSNA). Journal of Immunological Methods 292:1-2, 157-164
CrossRef121
Stephen Hoffman. (2004) Save the children. Nature 430:7002, 940-941
CrossRef122
Thomas L. Richie. (2004) Malaria vaccines for travelers. Travel Medicine and Infectious Disease 2:3-4, 193-210
CrossRef123
Jory R Baldridge, Patrick McGowan, Jay T Evans, Christopher Cluff, Sally Mossman, David Johnson, David Persing. (2004) Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opinion on Biological Therapy 4:7, 1129-1138
CrossRef124
Anne C. Moore, Adrian V. S. Hill. (2004) Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunological Reviews 199:1, 126-143
CrossRef125
Sunita S Balla-Jhagjhoorsingh, Gerrit Koopman, Petra Mooij, Wim Koornstra, Sheena McCormack, Jonathan Weber, Giuseppe Pantaleo, Jonathan L Heeney. (2004) Long-term persistence of HIV-1 vaccine-induced CD4+CD45RA???CD62L???CCR7??? memory T-helper cells. AIDS 18:6, 837-848
CrossRef126
L. J. M. Carvalho, S. G. Oliveira, M. Theisen, F. A. Alves, M. C. R. Andrade, G. M. Zanini, M. C. O. Brigido, C. Oeuvray, M. M. Povoa, J. A. P. C. Muniz, P. Druilhe, C. T. Daniel-Ribeiro. (2004) Immunization of Saimiri sciureus Monkeys with Plasmodium falciparum Merozoite Surface Protein-3 and Glutamate-Rich Protein Suggests that Protection is Related to Antibody Levels. Scandinavian Journal of Immunology 59:4, 363-372
CrossRef127
Judith E Epstein, Yupin Charoenvit, Kent E Kester, Ruobing Wang, Rhonda Newcomer, Steve Fitzpatrick, Thomas L Richie, Nadia Tornieporth, D.Gray Heppner, Chris Ockenhouse, Victoria Majam, Carolyn Holland, Esteban Abot, Harini Ganeshan, Mara Berzins, Trevor Jones, C.Nicole Freydberg, Jennifer Ng, Jon Norman, Daniel J Carucci, Joe Cohen, Stephen L Hoffman. (2004) Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. Vaccine 22:13-14, 1592-1603
CrossRef128
Gary R Matyas, Mangala Rao, Phillip R Pittman, Robert Burge, Iris E Robbins, Nabila M Wassef, Brandie Thivierge, Carl R Alving. (2004) Detection of antibodies to squalene. Journal of Immunological Methods 286:1-2, 47-67
CrossRef129
M. PINDER, W. H. H. REECE, M. PLEBANSKI, P. AKINWUNMI, K. L. FLANAGAN, E. A. M. LEE, T. DOHERTY, P. MILLIGAN, A. JAYE, N. TORNIEPORTH, R. BALLOU, K. P. M. J. MCADAM, J. COHEN, A. V. S. HILL. (2004) Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia. Clinical and Experimental Immunology 135:2, 286-293
CrossRef130
Valérie Vantomme, Christine Dantinne, Noreddine Amrani, Philippe Permanne, Dirk Gheysen, Claudine Bruck, Gerrit Stoter, Cedrik M. Britten, Ulrich Keilholz, Cor H. J. Lamers, Marie Marchand, Marcel Delire, Maryse Guéguen. (2004) Immunologic Analysis of a Phase I/II Study of Vaccination with MAGE-3 Protein Combined with the AS02B Adjuvant in Patients with MAGE-3-Positive Tumors. Journal of Immunotherapy 27:2, 124-135
CrossRef131
Jun Lu, K.N. Jayaprakash, Bert Fraser-Reid. (2004) First synthesis of a malarial prototype: a fully lipidated and phosphorylated GPI membrane anchor. Tetrahedron Letters 45:4, 879-882
CrossRef132
Jung-Yeon KIM, Naoaki YOKOYAMA, Sanjay KUMAR, Noboru INOUE, Kozo FUJISAKI, Chihiro SUGIMOTO. (2004) Molecular Characterization of Theileria orientalis Piroplasm Protein Encoded by an Open Reading Frame (To ORF2) in a Genomic Fragment. Journal of Veterinary Medical Science 66:8, 957-963
CrossRef133
Kathryn Maitland, Phillip Bejon, Charles R.J.C. Newton. (2003) Malaria. Current Opinion in Infectious Diseases 16:5, 389-395
CrossRef134
Claude Leclerc. (2003) New approaches in vaccine development. Comparative Immunology, Microbiology and Infectious Diseases 26:5-6, 329-341
CrossRef135
Peter J. Hotez, James Ashcom, Bin Zhan, Jeffrey Bethony, Alex Loukas, John Hawdon, Yang Wang, Qun Jin, Karen C. Jones, Azra Dobardzic, Reshad Dobardzic, Janelle Bolden, Idong Essiet, Walter Brandt, Philip K. Russell, Bernard C. Zook, Brian Howard, Marco Chacon. (2003) Effect of Vaccination with a Recombinant Fusion Protein Encoding an Astacinlike Metalloprotease (MTP-1) Secreted by Host-Stimulated Ancylostoma caninum Third-Stage Infective Larvae. Journal of Parasitology 89:4, 853-855
CrossRef136
William M. Stauffer, Deepak Kamat, Alan J. Magill. (2003) Traveling with Infants and Children. Part IV: Insect Avoidance and Malaria Prevention. Journal of Travel Medicine 10:4, 225-240
CrossRef137
Evelina Angov, Barbara M. Aufiero, Ann Marie Turgeon, Michel Van Handenhove, Christian F. Ockenhouse, Kent E. Kester, Douglas S. Walsh, Jana S. McBride, Marie-Claude Dubois, Joe Cohen, J.David Haynes, Kenneth H. Eckels, D.Gray Heppner, W.Ripley Ballou, Carter L. Diggs, Jeffrey A. Lyon. (2003) Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-142 malaria vaccine. Molecular and Biochemical Parasitology 128:2, 195-204
CrossRef138
Robert Edelman. (2003) Survey of human-use adjuvants. Expert Review of Vaccines 2:2, 167-188
CrossRef139
Nathalie Garçon, D Gray Heppner, Joe Cohen. (2003) Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Review of Vaccines 2:2, 231-238
CrossRef140
Jay T Evans, Christopher W Cluff, David A Johnson, Michael J Lacy, David H Persing, Jory R Baldridge. (2003) Enhancement of antigen-specific immunity via the TLR4 ligands MPL™ adjuvant and Ribi.529. Expert Review of Vaccines 2:2, 219-229
CrossRef141
P Graves, H Gelband, Patricia Graves. 2003. Vaccines for preventing malaria. .
CrossRef142
Robert Schwenk, Ludmila V. Asher, Isaac Chalom, David Lanar, Peifang Sun, Katherine White, Deborah Keil, Kent E. Kester, Jose Stoute, D. Gray Heppner, Urszula Krzych. (2003) Opsonization by antigen-specific antibodies as a mechanism of protective immunity induced by Plasmodium falciparum circumsporozoite protein-based vaccine. Parasite Immunology 25:1, 17-25
CrossRef143
Sócrates Herrera, Blanca Liliana Perlaza, Anilza Bonelo, Myriam Arévalo-Herrera. (2002) Aotus monkeys: their great value for anti-malaria vaccines and drug testing. International Journal for Parasitology 32:13, 1625-1635
CrossRef144
Robert Edelman, Steven S Wasserman, James G Kublin, Sacared A Bodison, Elizabeth H Nardin, Giane A Oliveira, Sobia Ansari, Carter L Diggs, Oscar L Kashala, Barbara J Schmeckpeper, Robert G Hamilton. (2002) Immediate-type hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites. Vaccine 21:3-4, 269-280
CrossRef145
Louis Vernacchio, Henry Bernstein, Steve Pelton, Carole Allen, Kristin MacDonald, Jessica Dunn, David D. Duncan, Grace Tsao, Vincent LaPosta, John Eldridge, Suzanne Laussucq, Donna M. Ambrosino, Deborah C. Molrine. (2002) Effect of monophosphoryl lipid A (MPL®) on T-helper cells when administered as an adjuvant with pneumocococcal–CRM197 conjugate vaccine in healthy toddlers. Vaccine 20:31-32, 3658-3667
CrossRef146
Wania Renata Santos, Valeria M.F de Lima, Edilma Paraguai de Souza, Robson Ronney Bernardo, Marcos Palatnik, Clarisa Beatriz Palatnik de Sousa. (2002) Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine 21:1-2, 30-43
CrossRef147
Pierre Druilhe, Paul Hagan, Graham A.W Rook. (2002) The importance of models of infection in the study of disease resistance. Trends in Microbiology 10:10, s38-s46
CrossRef148
Andrew W Taylor-Robinson. (2002) Exoerythrocytic malaria vaccine development: understanding host–parasite immunobiology underscores strategic success. Expert Review of Vaccines 1:3, 317-340
CrossRef149
David S. Peterson, Yan Gao, Kokila Asokan, Jacek Gaertig. (2002) The circumsporozoite protein of Plasmodium falciparum is expressed and localized to the cell surface in the free-living ciliate Tetrahymena thermophila. Molecular and Biochemical Parasitology 122:2, 119-126
CrossRef150
Florence Boisgérault, Gabriel Morón, Claude Leclerc. (2002) Virus-like particles: a new family of delivery systems. Expert Review of Vaccines 1:1, 101-109
CrossRef151
Pierre Vandepapelière. (2002) Therapeutic vaccination against chronic viral infections. The Lancet Infectious Diseases 2:6, 353-367
CrossRef152
Carl R. Alving. (2002) Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 20, S56-S64
CrossRef153
Oscar Kashala, Roberto Amador, Maria V. Valero, Alberto Moreno, Arnoldo Barbosa, Beatrice Nickel, Claudia A. Daubenberger, Fanny Guzman, Gerd Pluschke, Manuel.E. Patarroyo. (2002) Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine 20:17-18, 2263-2277
CrossRef154
Hua-Xin Liao, George J. Cianciolo, Herman F. Staats, Richard M. Scearce, Dana M. Lapple, Stephen H. Stauffer, James R. Thomasch, Salvatore V. Pizzo, David C. Montefiori, Michael Hagen, John Eldridge, Barton F. Haynes. (2002) Increased immunogenicity of HIV envelope subunit complexed with α2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF. Vaccine 20:17-18, 2396-2403
CrossRef155
A Rafi-Janajreh. (2002) Influence of adjuvants in inducing immune responses to different epitopes included in a multiepitope, multivalent, multistage Plasmodium falciparum candidate vaccine (FALVAC-1) in outbred mice. Experimental Parasitology 101:1, 3-12
CrossRef156
G. V. Brown, M. F. Good. (2002) Prospects for a vaccine against malaria. Internal Medicine Journal 32:4, 129-131
CrossRef157
Myriam Arevalo-Herrera, Anais Zully Valencia, Juana Vergara, Anilza Bonelo, Katharina Fleischhauer, John Mario Gonzalez, Juan Carlos Restrepo, Jose Alejandro Lopez, Danila Valmori, Giampietro Corradin, Socrates Herrera. (2002) Identification of HLA-A2 restricted CD8+ T-lymphocyte responses to Plasmodium vivax circumsporozoite protein in individuals naturally exposed to malaria. Parasite Immunology 24:3, 161-169
CrossRef158
C Zheng. (2002) Recombinant Mycobacterium bovis BCG producing the circumsporozoite protein of Plasmodium falciparum FCC-1/HN strain induces strong immune responses in BALB/c mice. Parasitology International 51:1, 1-7
CrossRef159
Myriam Arévalo-Herrera, Sócrates Herrera. (2001) Plasmodium vivax malaria vaccine development. Molecular Immunology 38:6, 443-455
CrossRef160
Moriya Tsuji, Fidel Zavala. (2001) Peptide-based subunit vaccines against pre-erythrocytic stages of malaria parasites. Molecular Immunology 38:6, 433-442
CrossRef161
David R Milich, Janice Hughes, Joyce Jones, Matti Sällberg, Tom R Phillips. (2001) Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate. Vaccine 20:5-6, 771-788
CrossRef162
Kalifa A Bojang, Paul JM Milligan, Margaret Pinder, Laurence Vigneron, Ali Alloueche, Kent E Kester, W Ripley Ballou, David J Conway, William HH Reece, Philip Gothard, Lawrence Yamuah, Martine Delchambre, Gerald Voss, Brian M Greenwood, Adrian Hill, Keith PWJ McAdam, Nadia Tornieporth, Joe D Cohen, Tom Doherty. (2001) Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. The Lancet 358:9297, 1927-1934
CrossRef163
Dharmendar Rathore, Sanjai Kumar, David E Lanar, Thomas F McCutchan. (2001) Disruption of disulfide linkages of the Plasmodium falciparum circumsporozoite protein: effects on cytotoxic and antibody responses in mice. Molecular and Biochemical Parasitology 118:1, 75-82
CrossRef164
Michael F. Good. (2001) TOWARDS A BLOOD-STAGE VACCINE FOR MALARIA: ARE WE FOLLOWING ALL THE LEADS?. Nature Reviews Immunology 1:2, 117-125
CrossRef165
Marc Dupuis, Kimberly Denis-Mize, Allyson LaBarbara, Wendy Peters, Israel F. Charo, Donald M. McDonald, Gary Ott. (2001) Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. European Journal of Immunology 31:10, 2910-2918
CrossRef166
P. Moingeon, J. Haensler, A. Lindberg. (2001) Towards the rational design of Th1 adjuvants. Vaccine 19:31, 4363-4372
CrossRef167
Jorge E. Suarez, Mauricio Urquiza, Alvaro Puentes, Javier E. Garcia, Hernando Curtidor, Marisol Ocampo, Ramses Lopez, Luis E. Rodriguez, Ricardo Vera, Marcia Cubillos, Maria H. Torres, Manuel E. Patarroyo. (2001) Plasmodium falciparum circumsporozoite (CS) protein peptides specifically bind to HepG2 cells. Vaccine 19:31, 4487-4495
CrossRef168
Blanca Liliana Perlaza, Jean-Pierre Sauzet, Aissatou Toure Balde, Karima Brahimi, Adama Tall, Giampietro Corradin, Pierre Druilhe. (2001) Long synthetic peptides encompassing thePlasmodium falciparum LSA3 are the target of human B and T cells and are potent inducers of B helper, T helper and cytolytic T cell responses in mice. European Journal of Immunology 31:7, 2200-2209
CrossRef169
Douglas C Waite, Eric W Jacobson, Francis A Ennis, Robert Edelman, Bernadette White, Robert Kammer, Christine Anderson, Charlotte R Kensil. (2001) Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 19:28-29, 3957-3967
CrossRef170
Karen G Heal, Nadeem A Sheikh, Michael R Hollingdale, W.John W Morrow, Andrew W Taylor-Robinson. (2001) Potentiation by a novel alkaloid glycoside adjuvant of a protective cytotoxic T cell immune response specific for a preerythrocytic malaria vaccine candidate antigen. Vaccine 19:30, 4153-4161
CrossRef171
José Alejandro López, Christophe Weilenman, Régine Audran, Mario A. Roggero, Anilza Bonelo, Jean-Marie Tiercy, François Spertini, Giampietro Corradin. (2001) A synthetic malaria vaccine elicits a potent CD8+ and CD4+ T lymphocyte immune response in humans. Implications for vaccination strategies. European Journal of Immunology 31:7, 1989-1998
CrossRef172
Martine Monette, Stanley J. Opella, Judith Greenwood, Anne E. Willis, Richard N. Perham. (2001) Structure of a malaria parasite antigenic determinant displayed on filamentous bacteriophage determined by NMR spectroscopy: Implications for the structure of continuous peptide epitopes of proteins. Protein Science 10:6, 1150-1159
CrossRef173
Yong-Jae Kim, David Y. Gin. (2001) Synthesis of the Trisaccharide Portion of the Immunologic Adjuvant QS-21A via Sulfonium-Mediated Oxidative and Dehydrative Glycosylation. Organic Letters 3:12, 1801-1804
CrossRef174
Antoniana U. Krettli, Louis H. Miller. (2001) Malaria: A sporozoite runs through it. Current Biology 11:10, R409-R412
CrossRef175
Moriya Tsuji, Elaine G. Rodrigues, Ruth S. Nussenzweig. (2001) Progress toward a Malaria Vaccine: Efficient Induction of Protective Anti-Malaria Immunity. Biological Chemistry 382:4, 553-570
CrossRef176
Fabio T.M Costa, Georges Snounou, Franck Letourneur, Nicolas Lebrun, Irène Landau, Laurent Rénia. (2001) The primary structure of the circumsporozoite protein of Plasmodium atheruri, a malaria parasite of the African porcupine Atherurus africanus. Molecular and Biochemical Parasitology 114:1, 125-127
CrossRef177
Dante J. Marciani, Ashish K. Pathak, Robert C. Reynolds, Lainne Seitz, Richard D. May. (2001) Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins. International Immunopharmacology 1:4, 813-818
CrossRef178
C.M Gérard, N Baudson, K Kraemer, C Bruck, N Garçon, Y Paterson, Z.K Pan, D Pardoll. (2001) Therapeutic potential of protein and adjuvant vaccinations on tumour growth. Vaccine 19:17-19, 2583-2589
CrossRef179
Anne Charlotte Grüner, Karima Brahimi, Wijnand Eling, Ruud Konings, Jacques Meis, Masamichi Aikawa, Pierre Daubersies, Claudine Guérin-Marchand, Sylvie Mellouk, Georges Snounou, Pierre Druilhe. (2001) The Plasmodium falciparum knob-associated PfEMP3 antigen is also expressed at pre-erythrocytic stages and induces antibodies which inhibit sporozoite invasion. Molecular and Biochemical Parasitology 112:2, 253-261
CrossRef180
Carmen Ochoa, Antonio R Martinez. (2001) Antiparasitic protozoan vaccines. Expert Opinion on Therapeutic Patents 11:2, 211-219
CrossRef181
Anthony W. Stowers, Yanling Zhang, Richard L. Shimp, David C. Kaslow. (2001) Structural conformers produced during malaria vaccine production in yeast. Yeast 18:2, 137-150
CrossRef182
Galindo, Acosta, Schellenberg, Aponte, Roca, Oettli, Urassa, Armstrong Schellenberg, Kahigwa, Ascaso, Mshinda, Lwilla, Vidal, Menendez, Tanner, Alonso. (2000) Humoral immune responses during a malaria vaccine trial in Tanzanian infants. Parasite Immunology 22:9, 437-443
CrossRef183
Magdalena Plebanski, Adrian VS Hill. (2000) The immunology of malaria infection. Current Opinion in Immunology 12:4, 437-441
CrossRef184
Lbachir Benmohamed, Alan Thomas, Marc Bossus, Karima Brahimi, Jacqueline Wubben, Hélène Gras-Masse, Pierre Druilhe. (2000) High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules. Vaccine 18:25, 2843-2855
CrossRef185
Thong P. Le, Kevin M. Coonan, Richard C. Hedstrom, Yupin Charoenvit, Martha Sedegah, Judith E. Epstein, Sanjai Kumar, Ruobing Wang, Denise L. Doolan, Jason D. Maguire, Suezanne E. Parker, Peter Hobart, Jon Norman, Stephen L. Hoffman. (2000) Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 18:18, 1893-1901
CrossRef186
Ali Alloueche, Henrique Silveira, David J. Conway, Kalifa Bojang, Tom Doherty, Joe Cohen, Margaret Pinder, Brian M. Greenwood. (2000) High-throughput sequence typing of T-cell epitope polymorphisms in Plasmodium falciparum circumsporozoite protein. Molecular and Biochemical Parasitology 106:2, 273-282
CrossRef187
Mark J Newman. (2000) Vaccines adjuvants. Expert Opinion on Therapeutic Patents 10:3, 279-314
CrossRef188
Frederico GC Abath. (2000) Development of vaccines against human parasitic diseases: tools, current status and perspectives. Expert Opinion on Investigational Drugs 9:2, 301-310
CrossRef189
S. McCormack, A. Tilzey, A. Carmichael, F. Gotch, J. Kepple, A. Newberry, G. Jones, S. Lister, S. Beddows, R. Cheingsong, A. Rees, A. Babiker, J. Banatvala, C. Bruck, J. Darbyshire, D. Tyrrell, C. Van Hoecke, J. Weber. (2000) A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320. Vaccine 18:13, 1166-1177
CrossRef190
C. P. Talwar. (1999) Vaccines and passive immunological approaches for the control of fertility and hormone-dependent cancers. Immunological Reviews 171:1, 173-192
CrossRef191
Jory R. Baldridge, R.Thomas Crane. (1999) Monophosphoryl Lipid A (MPL) Formulations for the Next Generation of Vaccines. Methods 19:1, 103-107
CrossRef192
Allan Saul, Gregor Lawrence, Anne Smillie, Christine M. Rzepczyk, Carol Reed, Darrin Taylor, Karen Anderson, Anthony Stowers, Richard Kemp, Anthony Allworth, Robin F. Anders, Graham V. Brown, David Pye, Peter Schoofs, David O. Irving, Shanny L. Dyer, Graeme C. Woodrow, William R.S. Briggs, Rosemaria Reber, Dieter Stürchler. (1999) Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine 17:23-24, 3145-3159
CrossRef193
Trevor R. Jones, Nicanor Obaldia, Robert A. Gramzinski, Yupin Charoenvit, Nelly Kolodny, Svetlana Kitov, Heather L. Davis, Arthur M. Krieg, Stephen L. Hoffman. (1999) Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine 17:23-24, 3065-3071
CrossRef194
Camila I. de Oliveira, Gerhard Wunderlich, Gabriela Levitus, Irene S. Soares, Mauricio M. Rodrigues, Moriya Tsuji, Hernando A. del Portillo. (1999) Antigenic properties of the merozoite surface protein 1 gene of Plasmodium vivax. Vaccine 17:23-24, 2959-2968
CrossRef195
Dirk C. de Graaf, Furio Spano, Franz Petry, Serge Sagodira, Alain Bonnin. (1999) Speculation on whether a vaccine against cryptosporidiosis is a reality or fantasy. International Journal for Parasitology 29:8, 1289-1306
CrossRef196
Michael F Good, Denise L Doolan. (1999) Immune effector mechanisms in malaria. Current Opinion in Immunology 11:4, 412-419
CrossRef197
C.Alberto Moreno, Raúl Rodriguez, Giane A Oliveira, Viviana Ferreira, Ruth S Nussenzweig, Z.Rosa Moya Castro, J.Mauricio Calvo-Calle, Elizabeth Nardin. (1999) Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice. Vaccine 18:1-2, 89-99
CrossRef198
Ricardo San Martín, Reinaldo Briones. (1999) Industrial uses and sustainable supply ofQuillaja saponaria (Rosaceae) saponins. Economic Botany 53:3, 302-311
CrossRef199
Magdalena Plebanski, Katie L Flanagan, Edwin A.M Lee, William H.H Reece, Keith Hart, Colin Gelder, Geraldine Gillespie, Margaret Pinder, Adrian V.S Hill. (1999) Interleukin 10–Mediated Immunosuppression by a Variant CD4 T Cell Epitope of Plasmodium falciparum. Immunity 10:6, 651-660
CrossRef200
Katie L. Flanagan, Magdalena Plebanski, Peter Akinwunmi, Edwin A. M. Lee, William H. H. Reece, Kathryn J. H. Robson, Adrian V. S. Hill, Margaret Pinder. (1999) Broadly distributed T cell reactivity, with no immunodominant loci, to the pre-erythrocytic antigen thrombospondin-related adhesive protein ofPlasmodium falciparum in West Africans. European Journal of Immunology 29:6, 1943-1954
CrossRef201
Pramatha R. Bhattacharya. (1999) Genetic polymorphism in T-cell epitopes of the circumsporozoite protein of Plasmodium falciparum clones and isolates from India. Transactions of the Royal Society of Tropical Medicine and Hygiene 93:2, 204-207
CrossRef202
Richard F. Thompson, Dorsey M. Bass, Stephen L. Hoffman. (1999) TRAVEL VACCINES*. Infectious Disease Clinics of North America 13:1, 149-167
CrossRef203
K. Sasnauskas, O. Buzaite, F. Vogel, B. Jandrig, R. Razanskas, J. Staniulis, S. Scherneck, D. H. Krüger, R. Ulrich. (1999) Yeast Cells Allow High-Level Expression and Formation of Polyomavirus-Like Particles. Biological Chemistry 380:3, 381-386
CrossRef204
Mario Clerici, Stefania Piconi, Daria Trabattoni. (1999) Vaccine strategies for infectious diseases. Expert Opinion on Investigational Drugs 8:2, 95-106
CrossRef205
Paul Newton, BM, DPhil, MRCP, Nicholas White, DSc, MD, FRCP. (1999) MALARIA: New Developments in Treatment and Prevention. Annual Review of Medicine 50:1, 179-192
CrossRef206
Evelyn R. Brandt, Michael F. Good. (1999) Vaccine strategies to prevent rheumatic fever. Immunologic Research 19:1, 89-103
CrossRef207
K. Senior. (1999) DNA vaccine shows promise for malaria. Molecular Medicine Today 5:1, 2-3
CrossRef208
George F Mabeza, Mark Loyevsky, Victor R Gordeuk, Günter Weiss. (1999) Iron Chelation Therapy for Malaria. Pharmacology & Therapeutics 81:1, 53-75
CrossRef209
Magdalena Plebanski, Sarah C. Gilbert, Jörg Schneider, Carolyn M. Hannan, Guy Layton, Tom Blanchard, Marion Becker, Geoffrey Smith, Geoffrey Butcher, Robert E. Sinden, Adrian V. S. Hill. (1998) Protection fromPlasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. European Journal of Immunology 28:12, 4345-4355
CrossRef210
H.S.G Thompson, M.L Davies, M.J Watts, A.E Mann, F.P Holding, T O'Neill, J.T Beech, S.J Thompson, G.D Leesman, J.T Ulrich. (1998) Enhanced immunogenicity of a recombinant genital warts vaccine adjuvanted with monophosphoryl lipid A. Vaccine 16:20, 1993-1999
CrossRef211
Frederico G.C Abath, Silvia M.L Montenegro, Yara M Gomes. (1998) Vaccines against human parasitic diseases: an overview. Acta Tropica 71:3, 237-254
CrossRef212
L Gonzalez-Ceron. (1998) Plasmodium vivax:A Monoclonal Antibody Recognizes a Circumsporozoite Protein Precursor on the Sporozoite Surface,. Experimental Parasitology 90:3, 203-211
CrossRef213
Samuel L Stanley. (1998) Malaria vaccines: are seven antigens better than one?. The Lancet 352:9135, 1163-1164
CrossRef214
Charlotte Read Kensil, Robert Kammer. (1998) QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opinion on Investigational Drugs 7:9, 1475-1482
CrossRef215
CHAKRIT HIRUNPETCHARAT, DANIELLE STANISIC, XUE QIN LIU, JIM VADOLAS, RICHARD A. STRUGNELL, ROGAN LEE, LOUIS H. MILLER, DAVID C. KASLOW, MICHAEL F. GOOD. (1998) Intranasal immunization with yeast-expressed 19 kD carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (yMSP1 19 ) induces protective immunity to blood stage malaria infection in mice. Parasite Immunology 20:9, 413-420
CrossRef216
Ross L Coppel, Graham V Brown, Victor Nussenzweig. (1998) Adhesive proteins of the malaria parasite. Current Opinion in Microbiology 1:4, 472-481
CrossRef217
Wendy R Pyper, Marina Tchavtchitch, Allan Saul. (1998) The circumsporozoite protein of Plasmodium chabaudi contains a large, pre-region I repeat domain1Note: Nucleotide sequence data reported in this paper are available in the EMBL, GenBank™ and DDBJ data bases under accession number AF043636.1. Molecular and Biochemical Parasitology 94:2, 287-289
CrossRef218
Kevin C. Kain, Jay S. Keystone. (1998) MALARIA IN TRAVELERS. Infectious Disease Clinics of North America 12:2, 267-284
CrossRef219
JIRI KOVARIK, CLAIRE-ANNE SIEGRIST. (1998) Optimization of vaccine responses in early life: The role of delivery systems and immunomodulators. Immunology and Cell Biology 76:3, 222-236
CrossRef220
Louis H. Miller, Stephen L. Hoffman. (1998) Research toward vaccines against malaria. Nature Medicine 4:5s, 520-524
CrossRef221
E.H. Nardin, J.M. Calvo-Calle, G.A. Oliveira, P. Clavijo, R. Nussenzweig, R. Simon, W. Zeng, K. Rose. (1998) Plasmodium falciparum polyoximes: highly immunogenic synthetic vaccines constructed by chemoselective ligation of repeat B-cell epitopes and a universal T-cell epitope of CS protein. Vaccine 16:6, 590-600
CrossRef222
Michael F. Good, David C. Kaslow, Louis H. Miller. (1998) PATHWAYS AND STRATEGIES FOR DEVELOPING A MALARIA BLOOD-STAGE VACCINE*. Annual Review of Immunology 16:1, 57-87
CrossRef223
Petra Mooij, Mike van der Kolk, Willy M.J.M. Bogers, Peter J.F. ten Haaft, Peter Van Der Meide, Neil Almond, Jim Stott, Marguerite Deschamps, Dominique Labbe, Patricia Momin, Gerald Voss, Paul Von Hoegen, Claudine Bruck, Jonathan L. Heeney. (1998) A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian–human immunodeficiency virus infection. AIDS 12:5, F15-F22
CrossRef224
Brian Greenwood. (1998) Traditional medicine to DNA vaccines: the advance of medical research in West Africa. Tropical Medicine & International Health 3:3, 166-176
CrossRef225
H.D. Engers, T. Godal. (1998) Malaria Vaccine Development: Current Status. Parasitology Today 14:2, 56-64
CrossRef226
Thong P. Le, L.W. Preston Church, Giampietro Corradin, Robert L. Hunter, Yupin Charoenvit, Ruobing Wang, Patricia de la Vega, John Sacci, W. Ripley Ballou, Nelly Kolodny, Svetlana Kitov, Gregory M. Glenn, Roberta L. Richards, Carl R. Alving, Stephen L. Hoffman. (1998) Immunogenicity of Plasmodium falciparum circumsporozoite protein multiple antigen peptide vaccine formulated with different adjuvants. Vaccine 16:2-3, 305-312
CrossRef227
F.E.G. Cox. (1998) Control of coccidiosis: lessons from other sporozoa. International Journal for Parasitology 28:1, 165-179
CrossRef228
Dominic Kwiatkowski, Kevin Marsh. (1997) Development of a malaria vaccine. The Lancet 350:9092, 1696-1701
CrossRef229
Samuel L Katz. (1997) Future vaccines and a global perspective. The Lancet 350:9093, 1767-1770
CrossRef230
Myron M Levine, Orin S Levine. (1997) Influence of disease burden, public perception, and other factors on new vaccine development, implementation, and continued use. The Lancet 350:9088, 1386-1392
CrossRef231
I.T. Ling, S.A. Ogun, P. Momin, R.L. Richards, N. Garçon, J. Cohen, W.R. Ballou, A.A. Holder. (1997) Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use. Vaccine 15:14, 1562-1567
CrossRef232
William Trager, James B. Jensen. (1997) Continuous culture of Plasmodium falciparum: its impact on malaria research. International Journal for Parasitology 27:9, 989-1006
CrossRef233
Mara Gerloni, W. Ripley Ballou, Rosario Billetta, Maurizio Zanetti. (1997) Immunity to Plasmodium falciparum malaria sporozoites by somatic transgene immunization. Nature Biotechnology 15:9, 876-881
CrossRef234
Stephen L Hoffman, Denise L Doolan, Martha Sedegah, Ruobing Wang, Libia F Scheller, Anita Kumar, Walter R Weiss, Thong P Le, Dennis M Klinman, Peter Hobart, Jon A Norman, Richard C Hedstrom. (1997) Toward clinical trials of DNA vaccines against malaria. Immunology and Cell Biology 75:4, 376-381
CrossRef235
(1997) A Recombinant Circumsporozoite Protein Vaccine against Malaria. New England Journal of Medicine 336:24, 1759-1761
Full Text236
Kevin Marsh, Robert W Snow. (1997) 30 years of science and technology: the example of malaria. The Lancet 349, S1-S2
CrossRef237
Nussenzweig, Ruth S., Zavala, Fidel, . (1997) A Malaria Vaccine Based on a Sporozoite Antigen. New England Journal of Medicine 336:2, 128-130
Full Text238
Richard C. Hedstrom, Denise L. Doolan, Ruobing Wang, Malcolm J. Gardner, Anita Kumar, Martha Sedegah, Robert A. Gramzinski, John B. Sacci, Yupin Charoenvit, Walter R. Weiss, Michal Margalith, Jon A. Norman, Peter Hobart, Stephen L. Hoffman. (1997) The development of a multivalent DNA vaccine for malaria. Springer Seminars in Immunopathology 19:2, 147-159
CrossRef
- Letters
